KeifeRx

Also Clin2 Lewy body dementia; KFRX02 Clin2 Lewy body dementia; KFRX03 Clin0 ALS, Clin0 Lyme disease, Clin0 mast cell activated syndrome; KFRX04 Clin0 mastocytosis/urticaria, Clin0 mild cognitive impairment

KeifeRx is focused on developing innovative therapies for neurodegenerative and immune diseases. Their research centers around the role of autophagy in the progression of these conditions. KeifeRx is developing oral small molecules that can penetrate the blood-brain barrier and target specific kinases involved in neurodegenerative diseases. KeifeRx's small molecules are designed to target specific kinases involved in autophagy and inflammation. They aim to stimulate autophagy. KeifeRx's pipeline includes several promising drug candidates, including Nilotinib (KFRX01), a tyrosine kinase inhibitor being developed for the treatment of Alzheimer's disease, and Bosutinib (KFRX02), a tyrosine kinase inhibitor being developed for the treatment of Lewy body dementia. By targeting autophagy and reducing the buildup of toxic proteins, KeifeRx's therapies have the potential to slow down the progression of neurodegenerative diseases and improve patient outcomes.

Jobs: